Alpine Immune Sciences, Inc. (ALPN): Price and Financial Metrics


Alpine Immune Sciences, Inc. (ALPN): $6.50

0.18 (+2.85%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALPN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ALPN POWR Grades

  • ALPN scores best on the Quality dimension, with a Quality rank ahead of 79.78% of US stocks.
  • The strongest trend for ALPN is in Momentum, which has been heading up over the past 179 days.
  • ALPN ranks lowest in Momentum; there it ranks in the 24th percentile.

ALPN Stock Summary

  • Of note is the ratio of ALPINE IMMUNE SCIENCES INC's sales and general administrative expense to its total operating expenses; just 8.94% of US stocks have a lower such ratio.
  • ALPN's price/sales ratio is 9.16; that's higher than the P/S ratio of 88.26% of US stocks.
  • With a year-over-year growth in debt of -26.11%, ALPINE IMMUNE SCIENCES INC's debt growth rate surpasses just 11.8% of about US stocks.
  • Stocks that are quantitatively similar to ALPN, based on their financial statements, market capitalization, and price volatility, are TNGX, SGMO, IDYA, BLCM, and GRTS.
  • ALPN's SEC filings can be seen here. And to visit ALPINE IMMUNE SCIENCES INC's official web site, go to www.alpineimmunesciences.com.

ALPN Valuation Summary

  • In comparison to the median Healthcare stock, ALPN's price/sales ratio is 97.92% higher, now standing at 9.5.
  • ALPN's price/sales ratio has moved NA NA over the prior 91 months.

Below are key valuation metrics over time for ALPN.

Stock Date P/S P/B P/E EV/EBIT
ALPN 2022-11-25 9.5 1.7 -5.6 -3.7
ALPN 2022-11-23 9.0 1.6 -5.3 -3.4
ALPN 2022-11-22 9.4 1.6 -5.5 -3.6
ALPN 2022-11-21 9.5 1.7 -5.6 -3.7
ALPN 2022-11-18 9.5 1.7 -5.6 -3.6
ALPN 2022-11-17 9.4 1.6 -5.5 -3.6

ALPN Growth Metrics

    Its 3 year revenue growth rate is now at 8584.1%.
  • Its 3 year price growth rate is now at 7.7%.
  • Its 2 year price growth rate is now at 120%.
ALPN's revenue has moved up $30,227,000 over the prior 30 months.

The table below shows ALPN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 31.967 4.785 -54.286
2022-03-31 33.868 6.172 -47.217
2021-12-31 23.443 -15.248 -50.333
2021-09-30 24.556 -9.868 -41.508
2021-06-30 17.953 -45.394 -34.151
2021-03-31 11.448 23.807 -33.05

ALPN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALPN has a Quality Grade of C, ranking ahead of 68.11% of graded US stocks.
  • ALPN's asset turnover comes in at 0.122 -- ranking 247th of 682 Pharmaceutical Products stocks.
  • SELB, TXMD, and QGEN are the stocks whose asset turnover ratios are most correlated with ALPN.

The table below shows ALPN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.122 1 -0.458
2021-03-31 0.086 1 -0.661
2020-12-31 0.083 1 -0.777
2020-09-30 0.051 1 -1.140
2020-06-30 0.044 1 -0.895
2020-03-31 0.047 1 -0.716

ALPN Price Target

For more insight on analysts targets of ALPN, see our ALPN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.00 Average Broker Recommendation 1.25 (Strong Buy)

ALPN Stock Price Chart Interactive Chart >

Price chart for ALPN

ALPN Price/Volume Stats

Current price $6.50 52-week high $14.40
Prev. close $6.32 52-week low $4.82
Day low $6.09 Volume 92,500
Day high $6.50 Avg. volume 103,048
50-day MA $6.42 Dividend yield N/A
200-day MA $7.93 Market Cap 197.61M

Alpine Immune Sciences, Inc. (ALPN) Company Bio


Alpine Immune Sciences, Inc. is focused on developing novel protein‐based immunotherapies using its proprietary Variant Ig Domain vIgD platform technology. The vIgD platform is designed to interact with multiple targets, including many present in the immune synapse. Alpine’s vIgDs are developed using a process known as directed evolution, which can potentially produce proteins capable of either enhancing or diminishing an immune response and thereby may potentially apply therapeutically to both oncology and inflammatory diseases. The company formed following a July, 2017 merger with Nivalis Therapeutics.


ALPN Latest News Stream


Event/Time News Detail
Loading, please wait...

ALPN Latest Social Stream


Loading social stream, please wait...

View Full ALPN Social Stream

Latest ALPN News From Around the Web

Below are the latest news stories about ALPINE IMMUNE SCIENCES INC that investors may wish to consider to help them evaluate ALPN as an investment opportunity.

Alpine Immune Sciences Announces Participation in Fireside Chat at the 5th Annual Evercore ISI HealthCONx Conference

SEATTLE, November 22, 2022--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, November 30, 2022, at 12:35 p.m. ET/9:35 a.m. PT.

Yahoo | November 22, 2022

Alpine Immune Sciences Third Quarter 2022 Earnings: Misses Expectations

Alpine Immune Sciences ( NASDAQ:ALPN ) Third Quarter 2022 Results Key Financial Results Revenue: US$8.37m (down 1.7...

Yahoo | November 16, 2022

Alpine Immune Sciences, Inc. (ALPN) Reports Q3 Loss, Misses Revenue Estimates

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -320% and 59.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 14, 2022

Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2022 Financial Results

SEATTLE, November 14, 2022--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2022.

Yahoo | November 14, 2022

Alpine Immune Sciences to Report Third Quarter 2022 Financial Results

SEATTLE, November 07, 2022--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the company will release third quarter 2022 financial results on Monday, November 14, 2022, after the close of market. The Company will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day.

Yahoo | November 7, 2022

Read More 'ALPN' Stories Here

ALPN Price Returns

1-mo 0.78%
3-mo -18.03%
6-mo -27.78%
1-year -43.13%
3-year 117.39%
5-year -38.68%
YTD -53.07%
2021 9.92%
2020 228.13%
2019 4.35%
2018 -67.14%
2017 25.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8317 seconds.